Bend Research Boosts Client Base and Proprietary Capabilities
News Oct 27, 2009
Bend Research Inc., a company applying pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, is marking the one-year anniversary of a new initiative focused on meeting the needs of a broad range of U.S. and international clients.
In October 2008, Bend Research launched a new marketing effort aimed at expanding the company’s client roster and its proprietary service offerings. This expansion drive resulted from Bend Research’s near 20-year R&D relationship with Pfizer transitioning, after a decade of exclusivity, into a non-exclusive arrangement.
The result has been a expansion of the company’s client portfolio, including more than two dozen pharma and biotech companies.
According to Bend Research CEO Rod Ray, "Our rapid success with the new marketing effort is the result of our long track record of success in solving tough technical problems for clients, as well as broad-ranging expertise and great multi-disciplinary teams."
Ray said Bend Research clients also benefit from the company’s flexible business model, which emphasizes close collaboration with customers and client value creation.
New clients have asked Bend Research to solve a variety of development problems spanning the entire drug-discovery and development spectrum during the last year. The tasks range from early-stage drug formulation to advanced cGMP manufacturing of supplies for human clinical trials.
A major draw for Bend Research’s new clients is access to the company’s strong portfolio of proprietary and non-proprietary technologies, which can be applied on a case-by-case basis to their specific formulation or production challenges. These include oral solubilization, either alone or in combination with established oral controlled-release technologies, using tablets and multi-particulate dosage forms.
Bend Research also offers advanced engineering capabilities for the scale up and scale down of unit operations such as spray drying, hot melt extrusion, granulation, and tablet or bead coating.
During the past year, Bend Research has invested in further expanding the technology portfolio. The firm’s technologies include new solubility techniques for oral, ocular, parenteral and pulmonary delivery routes. Additionally, Bend Research is looking for partners wanting to develop advanced technologies such as oligonucleotide delivery.
WHO welcomes the Government of Malawi’s launch of the world’s first malaria vaccine today in a landmark pilot programme. The country is the first of three in Africa in which the vaccine, known as RTS,S, will be made available to children up to 2 years of age; Ghana and Kenya will introduce the vaccine in the coming weeks.READ MORE
Using EBX reagents, researchers have converted the C-terminal carboxylic acid of peptides into a carbon-carbon triple bond - an alkyne (in chemical jargon a "decarboxylative alkynylation"). The alkyne moiety is a very valuable functional group that can be used to further modify the peptides.READ MORE